EnGene Therapeutics Inc (ENGN)
enGene Therapeutics Inc. is a Nasdaq-listed common stock of a clinical-stage biotechnology company based in Montreal, Canada. Through its subsidiary enGene, Inc., the company focuses on developing genetic medicines for patients with bladder cancer. Its lead candidate is detalimogene voraplasmid, a monotherapy being studied for non-muscle invasive bladder cancer (NMIBC). The development pipeline also includes LEGEND, which is in Phase 2. The company was previously known as enGene Holdings Inc. before adopting its current name in April 2026.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ENGN
|
$2.52
|
32.7% Upside
|
Undervalued
|
$3.29
|
72.9% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
September 16, 2026
|
-1.0x
|
0.5x
|
—
|
125.3 M
|
-97.164 M
|
21.0%
|
33.6%
|
6.2
|
—
|
87.8%
|
